MindBio Therapeutics CEO Provides Video Update on Phase 2a Depression Trial Using MB22001

VANCOUVER, BC / ACCESSWIRE / October 24, 2023 / MindBio Therapeutics Corp. (CSE:MBIO); (Frankfurt:WF6), (the "Company" or "MindBio"), Chief Executive Officer Justin Hanka provides video update on Phase 2a Depression trial using MB22001. MindBio is …